Legalization of psychedelics

Since the 1960s and 1970s, psychedelics have been banned in most countries due to concerns about public safety, unpredictable hallucinogenic effects and their association with social unrest. For decades they were treated exclusively as dangerous substances with no medical value. Today, however, this narrative is changing.

A growing body of contemporary scientific research shows that certain psychedelics may support therapeutic work in areas such as depression, anxiety disorders, PTSD, end-of-life distress, addiction and other conditions that are difficult to treat with traditional methods. This has sparked a new global discussion on whether psychedelics should be made legally available in controlled, clinical settings.

Image by upklyak on Freepik

History of the legality of psychedelics

Psychedelics such as LSD, mescaline and psilocybin were discovered and explored scientifically from the 1940s onward. In the following decades they attracted increasing interest among psychiatrists, writers, artists and spiritual seekers. Early clinical trials showed promising results in treating addiction, depression and trauma, while philosophers and intellectuals used these substances to study consciousness.

The situation changed abruptly in the late 1960s and early 1970s.

As psychedelics spread beyond laboratories into counterculture movements, especially the hippie movement and anti-war protests, many governments reacted with prohibition. Substances once considered valuable research tools became classified as dangerous drugs. This restriction halted much of the scientific work of the time, forcing researchers either to abandon the field or to move abroad.

In recent years, however, the legal landscape has begun to shift once again. Some countries — including Canada and Portugal — allow limited, medically supervised use of certain psychedelics. Others, such as Germany, the Netherlands and parts of the United States, are actively debating policy changes or have introduced local legal pathways for therapeutic use. Despite this, psychedelics remain illegal in much of the world and public opinion is still divided.

Outlawing psychedelics in the context of the Vietnam War

The cultural and political climate of the Vietnam War played a significant role in the prohibition of psychedelics. These substances were associated with anti-war activists, the youth counterculture and rapid social change. Government officials feared that psychedelics encouraged rebellion, non-conformity and refusal to participate in military service.

In 1970, the United States passed the Controlled Substances Act, which classified LSD, psilocybin and similar substances as Schedule I drugs — meaning “no accepted medical use” and “high potential for abuse.” Many other countries followed suit. The decision effectively shut down scientific work and criminalized entire subcultures.

The consequences were long-lasting. Clinical research almost disappeared for decades, and public understanding of psychedelics became shaped by stigma rather than evidence. Only recently has research slowly re-started, driven by universities, independent foundations and medical institutions.

Legalization of psychedelics from the perspective of the pharmaceutical industry

The pharmaceutical industry plays a significant role in shaping drug policy, and its relationship with psychedelics is complex. Several factors contribute to corporate skepticism:

1. Lack of patentability and recurring revenue.
Classic psychedelics — such as psilocybin, LSD or mescaline — are naturally occurring or long-known molecules, which means they cannot be patented in their original form. Drug companies typically invest in medications that can generate long-term, repeat-dose revenue. Psychedelics, by contrast, tend to work in single or infrequent sessions combined with psychotherapy, which limits profit potential.

2. High regulatory and clinical requirements.
Approving any psychiatric medication requires extensive research, and psychedelic-assisted therapy involves not only the substance but also professional therapeutic support. This makes research costly, complex and difficult to scale on a traditional pharmaceutical model. Many companies prefer to invest in drug categories with more predictable commercial pathways.

3. Market disruption.
Legal psychedelic therapy could, in theory, offer an alternative to long-term antidepressant use. This is viewed by some critics as economically unfavorable to pharmaceutical companies whose business model is based on chronic medication rather than rapid, session-based treatments that may offer sustained improvement.

For these reasons, some pharmaceutical actors view the growth of psychedelic medicine cautiously — although a new wave of biotech companies is actively exploring synthetic analogues, new formulations and patented derivatives.

The content on the psychodelicroom.pl website is educational, research-based, and expresses many opinions that should be treated with caution. We advise against using any substances that affect consciousness, as all of these substances can both heal and be very harmful. In particular, we advise against cultivating mushrooms from growkits in countries where it is illegal — including Poland — because it involves criminal liability. We recommend that you dispose of the growkits purchased from us within 72 hours of receiving them.